OnCo

Retinoic acid receptor alpha (RARA)

Short target page →

The retinoic acid receptor that, fused to PML in acute promyelocytic leukaemia, blocks white blood cells from maturing. All-trans retinoic acid releases the block and arsenic trioxide destroys the fusion protein, turning a once rapidly fatal leukaemia into one of the most curable. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.

Biology

Ligand-activated nuclear receptor of myeloid differentiation; the PML::RARA fusion in APL is the drug target of tretinoin and arsenic trioxide.

Where it is found
  • Acute promyelocytic leukaemia (PML::RARA fusion in almost all cases)
Class: nuclear receptor · Gene: RARA · Facts checked 2026-09-04 · Target page

External identifiers

Built from HGNC, Ensembl, UniProt and ChEMBL ids

Products by modality and phase

Browse products →

No product in the corpus is aimed at this target yet.

No trial in the corpus names this target or one of its products.

Resistance routes

Unaddressed routes →

The resistance atlas has no route that names this target.

No pathway diagram carries this target as a node.

Companion diagnostics

Assay registry →

No companion diagnostic in the registry measures this target.

Preclinical models

All models →

No model entry for this target yet; check the cancer entries on the models page.

No open questions recorded for this target yet. Suggest one.

Literature

Preprints →
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"Retinoic acid receptor alpha" OR ABSTRACT:"Retinoic acid receptor alpha" OR TITLE:"RARA" OR ABSTRACT:"RARA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Retinoic acid receptor alpha (RARA), not a curated reading list.

Export

The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/rara.json. Licence CC BY-NC 4.0.